UPDATE: Goldman Sachs Color on Alere PT Decrease

), is providing some color on the stock. “We believe the sell-off related to warfarin concerns was overdone,” Goldman Sachs writes. “We estimate that the impact of the new factor 10a's will have less than a 100 bp impact to ALR's organic growth rate over the next three years as it impacts just 3% of total revenues. “We have also added granularity to our assumptions for new products (CD4/epoc/Heart Check). The net effect of reduced warfarin testing expectations and new product assumptions is a 30 bp increase to our long-term revenue CAGR, which is now 6.2%. These higher revenue assumptions combine with a higher interest expense assumption (exclusive of the refinancing) to drive a $0.03 reduction in our FY2011 estimate. As a result, we revise our 2011-2013 EPS estimates to $2.68, $3.08, $3.57 from $2.71, $3.12, $3.44.” Alere closed Wednesday at $35.58.